Slide 1: Intimation under Regulation 30 to NSE for Investor Presentation
ĂƚĞ͗DĂLJϭϵ͕ϮϬϮϰ ZĞĨ͘EŽ͗͘<>ͬ^ͬϬϮϱͬϮϬϮϰͲϮϱ dŽ͕ dŽ͕ ^>ŝŵŝƚĞĚ EĂƚŝŽŶĂů^ƚŽĐŬdžĐŚĂŶŐĞŽĨ/ŶĚŝĂ>ŝŵŝƚĞĚ ŽƌƉŽƌĂƚĞZĞůĂƚŝŽŶƐŚŝƉĞƉĂƌƚŵĞŶƚ džĐŚĂŶŐĞWůĂnjĂ͕WůŽƚEŽ͘Ͳϭ͕ůŽĐŬ'͕ ϮϱƚŚ&ůŽŽƌ͕WŚŝƌŽnjĞ:ĞĞũĞĞLJdŽǁĞƌƐ ĂŶĚƌĂ<ƵƌůĂŽŵƉůĞdž͕ĂŶĚƌĂ;ĂƐƚͿ ĂůĂů^ƚƌĞĞƚ͕DƵŵďĂŝͲϰϬϬϬϬϭ DƵŵďĂŝʹϰϬϬϬϱϭ ^ĐƌŝƉŽĚĞ͗ϱϰϯϯϮϴ E^^LJŵďŽů͗<Z^E ĞĂƌ^ŝƌͬDĂĚĂŵ͕ ^Ƶď
Slide 2: FY2024 Result Presentation
FY2024 Result Presentation One of INDIA’S LARGEST Differentiated Diagnostic Service Provider May 2024
Slide 3: FY2024 Performance
@® FY2024 Performance
Slide 4: Krsnaa Diagnostics FY24 Operations at a Glance
Krsnaa Diagnostics Krsnaa FY24 – Operations Operations- Diagnostics At a Glance at a Glance Radiology Pathology 148 India's 1st 15Mn+ India’s 1st 120 CT/MRI Centres CAP Accreditation Patient served NABH Accredited Tele Processing lab in Govt. Hospital FY24 radiology HUB 1,443 1,895 Tele-Reporting Co
Slide 5: Krsnaa Diagnostics FY24 Financials at a Glance
Krsnaa Diagnostics Krsnaa FY24 – Financial- Diagnostics AtFinancials a Glance at a Glance In mn Delivering Excellence: Achieving 27 % YoY Revenue Growth and 18% YoY EBITDA Strengthening, on account of incremental revenues from newly launched centres & operational efficiencies Revenue from operation
Slide 6: EBITDA Analysis
EBITDA Analysis EBITDA Margins Before CSR and ESOP Gross Profit Margins FY 24Mix Segment Revenue & EBITDA Bifurcation New Centre Existing Centre 25% 24% 2336 c 33% Margin 183 3860 1283 FY23 FY24 Revenue EBIDTA EBIDTA Bridge Y-O-Y EBITDA Bridge 3
Slide 7: Q4 FY24 Financials at a Glance
Krsnaa Diagnostics Krsnaa Financial- Diagnostics Q4FY24 At a– Glance Financials at a Glance In mn Delivering Excellence: Achieving 25 % YoY Revenue Growth and 28% YoY EBITDA Strengthening, on account of incremental revenues from newly launched centres & operational efficiencies Revenue from operatio
Slide 8: Financial Performance
Financial Performance Financial Performance In mn Particulars Q4 FY 24 Q3 FY 24 Q4 FY 23 FY 24 FY 23 Amount % Amount % Amount % Amount % Amount % Revenue from operations 1,663 1,583 1,332 6,196 4,871 Expenses Cost of Material Consumed 430 26% 344 22% 257 19% 1,410 23% 742 15% Employee benefits expen
Slide 9: Financial Performance: Assets and Liabilities
Financial Performance (INR In Mn) Assets Mar 31, 2024 Mar 31, 2023 Liabilities Mar 31, 2024 Mar 31, 2023 Non-current assets Equity Equity share capital 161.45 156.99 Property, plant and equipment 6447.21 4678.47 Other equity 7936.57 7230.37 Capital work-in-progress 98.45 254.80 Total equity 8098.02
Slide 10: Operational Highlights
@® Operational Highlights
Slide 11: Krsnaa Diagnostics Revenue Bifurcation
Krsnaa Diagnostics Krsnaa – Revenue Financial- Diagnostics At a Glance Bifurcation In mn Radiology Pathology Total – 148 Centres Total – 2,015 Lab & Centres -- CT Machine : 109 -- MRI Machine : 39 57% vs 43% -- Labs: 120 -- Collection Centres:1,895 Tele-Reporting Centres:1,443 938 858 891 870 845 83
Slide 12: Only Company with Pan India Presence in Both Radiology and Pathology
Only OnlyCompany with Company with Pan Pan India India Presence Presence inRadiology in Both Both Radiology and Pathology and Pathology Well Diversified Regional Revenue Mix 6% 35% 36% FY2024 23% West South North East High Headroom to Grow Highest penetration across districts with presence in 150+
Slide 13: Centres Maturity Profile
Centres Maturity Centres Profile Maturity Profile Krsnaa Younger Portfolio Continues to Mature with Promising Future 14% -22% 49% 20% 37% 35% Net ROCE Net ROCE Net ROCE Block* Block* Block* Notes: 1. * Net Block % is calculated as on the year ended 31 st March 2024 2. Maturity is on the basis of the
Slide 14: Recent Developments
@® Recent Developments
Slide 15: PPP Project Implementation on Track
PPP Project Project Implementation under on Track Implementation Radiology Centres Under Implementation Pathology Centres Under Implementation Total Centres Operational Under Total Centres Operational Under CONCEPT B CONCEPT B Implementation Implementation Uttar Pradesh 8 5 3 Mira Bhayandar 1 - 1 De
Slide 16: Way Forward
@® Way Forward
Slide 17: Growth Strategy
Growth Strategy Growth Strategy We aim to sustain the upward trajectory of our Revenue and PAT CAGR by utilizing our existing facilities and seizing opportunities in untapped markets Tap the growing and Focus on expanding and Enhanced centre Pathology business by Digital marketing underpenetrated le
Slide 18: Krsnaa Diagnostics Edge
Krsnaa Diagnostics Krsnaa Edge Diagnostics Edge ₹ Extensive Geographic Strong Scalable & Agile Competitive Stakeholder Value Footprint Brand Equity Business Model Pricing Creation Centres across India with Well positioned to partner PPP is an asset light model Ability to maintain cost Defined strate
Slide 19: Contact Information
Contact ContactInformation Information This presentation contains statements that are “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Krsnaa Diagnostics’ future business developments